Compugen Achieves Significant Milestones in Q4 and Full Year 2025 Financial Results Compugen announces strong financial results for Q4 and the full year of 2025, highlighting strategic partnerships and operational advancements.

Compugen Achieves Significant Milestones in Q4 and Full Year 2025 Financial Results #Israel #AstraZeneca #Compugen #Holon #Gilead

Compugen Welcomes Michele Holcomb, Ph.D. as New Board Member to Accelerate Growth Compugen Ltd. has appointed Michele Holcomb, Ph.D., as a new independent director. Her extensive experience in biotech and healthcare will bolster the company’s strategic direction.

Compugen Welcomes Michele Holcomb, Ph.D. as New Board Member to Accelerate Growth #Compugen #Holon #CGEN #Michele_Holcomb

Compugen Strikes Strategic Deal with AstraZeneca Worth up to $90 Million Compugen Ltd. has successfully monetized a portion of its future royalty rights with AstraZeneca, securing $90 million to enhance its immunotherapy pipeline.

Compugen Strikes Strategic Deal with AstraZeneca Worth up to $90 Million #Israel #AstraZeneca #Compugen #Holon #Rilvegostomig

Compugen's Third Quarter 2025 Financial Performance and Clinical Updates Highlight Its Strategic Direction Compugen Ltd. releases its financial results for Q3 2025, highlighting advancements in cancer immunotherapy and strategic collaborations that aim for impactful efficacy in treatment.

Compugen's Third Quarter 2025 Financial Performance and Clinical Updates Highlight Its Strategic Direction #Israel #Cancer_Immunotherapy #Compugen #Holon #COM701

Compugen's Upcoming Participation in Stifel 2025 Healthcare Conference Highlights Industry Innovations Compugen Ltd. announces its participation at the Stifel 2025 Healthcare Conference, showcasing advancements in cancer immunotherapy and AI technologies.

Compugen's Upcoming Participation in Stifel 2025 Healthcare Conference Highlights Industry Innovations #New_York_City #Israel #cancer_therapy #Compugen #AI_Drug_Discovery

Compugen Announces Upcoming Q3 2025 Financial Results and Corporate Update Compugen Ltd., a leader in cancer immunotherapy, will release its third quarter 2025 financial results on November 10, before U.S. markets open, with updates on its pipeline.

Compugen Announces Upcoming Q3 2025 Financial Results and Corporate Update #Israel #Immunotherapy #Compugen #Holon #CGEN

Compugen to Showcase COM701 Efficacy Analysis at ESMO 2025 for Ovarian Cancer Compugen Ltd. will present a pooled analysis of COM701 in ovarian cancer patients at ESMO 2025, highlighting its potential as a pivotal treatment.

Compugen to Showcase COM701 Efficacy Analysis at ESMO 2025 for Ovarian Cancer #Israel #Compugen #Holon #COM701 #OvarianCancer

Compugen Launches New Technology Centre in Montreal, Enhancing IT Services Across Canada Compugen opens a new technology center in Montreal, marking a significant milestone in supporting IT services nationally. The facility will enhance service delivery across various sectors.

Compugen Launches New Technology Centre in Montreal, Enhancing IT Services Across Canada #Canada #Montreal #IT_Services #Compugen #Technology_Centre

Compugen to Unveil Groundbreaking Cancer Immunotherapy Trial at SITC 2025 Compugen will present a pioneering clinical trial for the anti-IL18BP antibody COM503, aimed at advanced malignancies at SITC 2025.

Compugen to Unveil Groundbreaking Cancer Immunotherapy Trial at SITC 2025 #Israel #Compugen #Holon #COM503 #SITC_2025

Compugen Showcases Innovative Research at the Single Cell Genomics 2025 Conference Compugen Ltd. will present groundbreaking research at the upcoming Single Cell Genomics 2025 Conference in Stockholm, part of the company's pioneering work in cancer immunotherapy.

Compugen Showcases Innovative Research at the Single Cell Genomics 2025 Conference #Israel #Immunotherapy #Compugen #Holon #AI/ML

Compugen Announces Positive Developments in Cancer Therapy Trials and Financials for Q2 2025 Compugen Ltd. reports significant advancements in their cancer therapy trials and reveals solid financial standing for Q2 2025, promising growth ahead.

Compugen Announces Positive Developments in Cancer Therapy Trials and Financials for Q2 2025 #Israel #Cancer_Immunotherapy #Compugen #Holon #COM701

Compugen to Unveil COM701 Phase 1 Trials Analysis at ESMO 2025 in Berlin Discover Compugen's upcoming presentation focusing on the pooled analysis of COM701 Phase 1 trials for platinum-resistant ovarian cancer at ESMO 2025.

Compugen to Unveil COM701 Phase 1 Trials Analysis at ESMO 2025 in Berlin #Israel #Compugen #Holon #Ovarian_Cancer #COM701

Compugen Initiates Groundbreaking Trial for COM701 in Ovarian Cancer Treatment Compugen has officially started dosing patients in a global trial for COM701, an innovative therapy for platinum-sensitive ovarian cancer, aiming for improved patient outcomes.

Compugen Initiates Groundbreaking Trial for COM701 in Ovarian Cancer Treatment #Israel #Compugen #Holon #Ovarian_Cancer #COM701

Compugen Showcases Innovative AI/ML Research at Global Conferences on Cancer Immunotherapy Compugen Ltd. will present groundbreaking predictive computational research using AI/ML at major international cancer research conferences in 2025. Discover their advancements.

Compugen Showcases Innovative AI/ML Research at Global Conferences on Cancer Immunotherapy #Israel #Cancer_Research #Compugen #Holon #AI/ML

Compugen Unveils Promising Progress in Cancer Immunotherapy and Financial Stability Compugen reports Q1 2025 results, highlighting ongoing trials for novel cancer therapies and a strong financial outlook, guiding until 2027.

Compugen Unveils Promising Progress in Cancer Immunotherapy and Financial Stability #Israel #cancer_therapy #Compugen #Holon #COM701

Significant Leadership Changes at Compugen Planned for September 2025 Compugen is set to undergo major leadership transitions, with Dr. Anat Cohen-Dayag as Executive Chair and Dr. Eran Ophir as CEO effective September 2025.

Significant Leadership Changes at Compugen Planned for September 2025 #Israel #Compugen #Holon #Dr._Anat_Cohen-Dayag #Dr._Eran_Ophir

Compugen Reveals Upcoming Participation in Virtual Investor Conferences in April 2025 Compugen Ltd. is set to engage in several virtual investor conferences throughout April 2025, highlighting significant developments in cancer immunotherapy.

Compugen Reveals Upcoming Participation in Virtual Investor Conferences in April 2025 #Israel #Cancer_Immunotherapy #Compugen #Holon #virtual_conferences

Compugen Reports Promising Q4 and Full Year 2024 Financial Results and Development Milestones Compugen announces its fourth quarter and full year 2024 results, highlighting breakthroughs in cancer immunotherapy development and strong financial performance.

Compugen Reports Promising Q4 and Full Year 2024 Financial Results and Development Milestones #Israel #Compugen #Holon #Gilead #COM701

Compugen to Feature in Fireside Chat at Upcoming Global Healthcare Conference in Miami Beach Compugen Ltd. will present a fireside chat during the upcoming Leerink Partners Global Healthcare Conference in Miami Beach, offering insights on their cancer immunotherapy advancements.

Compugen to Feature in Fireside Chat at Upcoming Global Healthcare Conference in Miami Beach #United_States #Immunotherapy #Compugen #Miami_Beach #CGEN

Compugen Revolutionizes Cancer Research with Enhanced AI/ML Platform and Single Cell Sequencing Technology Compugen combines its AI/ML predictive platform Unigen™ with Ultima Genomics' UG 100™ technology, targeting improved cancer research and immunotherapy discovery. Explore the collaboration's breakthroughs.

Compugen Revolutionizes Cancer Research with Enhanced AI/ML Platform and Single Cell Sequencing Technology #Israel #Compugen #Holon #Unigen #Ultima_Genomics

Compugen Set to Showcase Innovations at Oppenheimer's 35th Annual Healthcare Life Sciences Conference Compugen will present at the Oppenheimer Healthcare Life Sciences Conference, highlighting advancements in cancer immunotherapy and computational discovery.

Compugen Set to Showcase Innovations at Oppenheimer's 35th Annual Healthcare Life Sciences Conference #Israel #Cancer_Immunotherapy #Compugen #Holon #computational_research

Compugen Advances Cancer Research with First Patient Dosed in Clinical Trial for COM503 and Zimberelimab Compugen has made a significant stride in cancer treatment with the first patient dosed in a clinical trial for COM503 and Zimberelimab. This innovative approach targets advanced solid tumors.

Compugen Advances Cancer Research with First Patient Dosed in Clinical Trial for COM503 and Zimberelimab #Israel #Compugen #Holon #COM503 #Zimberelimab

Compugen Boosts Cancer Treatment Potential with New Patent for COM902 and Antibody Combinations Compugen has received a new U.S. patent for COM902, enabling its use in combination therapies with anti-PD-1 and anti-PVRIG antibodies for cancer treatment.

Compugen Boosts Cancer Treatment Potential with New Patent for COM902 and Antibody Combinations #Israel #cancer_therapy #Compugen #COM902 #Holon